Pheochromocytoma is one of those diagnoses that attracts attention because the symptoms can be dramatic, but the condition itself is rare. A person may have pounding headaches, sudden surges of anxiety, sweats, shaking, palpitations, and blood pressure spikes that seem to come out of nowhere. That pattern can look like panic, migraine, thyroid disease, medication effects, or simply stress. In some cases, that is exactly what it is. In a smaller number of cases, though, those episodes point to a catecholamine-producing tumor that should not be missed.
That is what makes pheochromocytoma both important and tricky. It is not a common explanation for everyday high blood pressure or occasional palpitations, so testing everyone with vague symptoms would create more confusion than clarity. But there are specific patterns, risk factors, and testing strategies that make suspicion more targeted and useful. Knowing what symptoms fit, what testing usually comes first, and what false alarms can interfere with the workup helps turn a rare diagnosis into a practical one.
Essential Insights
- Pheochromocytoma is rare, but recognizing the right symptom pattern can speed diagnosis and prevent dangerous blood pressure surges.
- The classic episodes often involve headache, palpitations, sweating, tremor, and either sustained or sudden blood pressure elevation.
- Initial testing usually starts with plasma free metanephrines or 24-hour urinary fractionated metanephrines, not with imaging alone.
- Mildly abnormal results do not automatically confirm the diagnosis because medications, stress, and testing conditions can create false positives.
- A practical first step is to document spells carefully, including timing, blood pressure, triggers, medications, and any family history of related tumors or syndromes.
Table of Contents
- What Pheochromocytoma Is
- The Symptom Pattern That Raises Suspicion
- When the Diagnosis Becomes More Likely
- How Testing Usually Starts
- What Can Cause False Alarms
- What Happens After Diagnosis
- When to Suspect It and Get Checked
What Pheochromocytoma Is
Pheochromocytoma is a neuroendocrine tumor that arises from chromaffin cells in the adrenal medulla, the inner part of the adrenal gland. These tumors can produce excess catecholamines such as epinephrine, norepinephrine, and sometimes dopamine. Those hormones are part of the body’s normal stress-response system, but when they are released inappropriately or in large amounts, they can cause abrupt and sometimes dangerous symptoms.
A closely related tumor, called a paraganglioma, develops from similar cells outside the adrenal gland. In everyday clinical discussion, the two are often grouped together because the testing, genetics, and treatment strategy overlap substantially. Still, the distinction matters. A pheochromocytoma is adrenal. A paraganglioma is extra-adrenal. Both may produce catecholamines, though some head and neck paragangliomas do not.
These tumors are uncommon. That is worth emphasizing because people often encounter the diagnosis online while looking up headaches, panic-like spells, or difficult blood pressure. Most people with those symptoms do not have pheochromocytoma. At the same time, the diagnosis matters because untreated catecholamine excess can lead to cardiovascular complications, severe hypertension, arrhythmias, stroke, or a catecholamine crisis.
One reason pheochromocytoma is so clinically interesting is that it has changed from being a diagnosis made mostly in very sick patients to one that is sometimes found incidentally. Some tumors are discovered because of classic spells. Others are found during evaluation of an adrenal incidentaloma, during screening in families with hereditary syndromes, or when a person develops unusual hypertension at a relatively young age. This broader range of presentation is one reason the condition can be both under-recognized and over-imagined at the same time.
Genetics are also unusually important here. A substantial share of pheochromocytomas and paragangliomas are linked to hereditary pathogenic variants, including syndromes such as MEN2, von Hippel-Lindau disease, neurofibromatosis type 1, and SDHx-related conditions. That means family history, age at diagnosis, tumor location, and whether there are multiple tumors can all shape how the condition is evaluated and followed.
The most practical way to think about pheochromocytoma is as a rare but important cause of catecholamine excess. It is not the first explanation for ordinary stress symptoms, but it becomes more worth considering when there is a specific pattern of episodic symptoms, unusual hypertension, adrenal imaging findings, or hereditary risk. That balance matters. A good article on this topic should make the diagnosis easier to recognize without making it sound like the hidden answer to every fast heartbeat or anxious spell.
The Symptom Pattern That Raises Suspicion
The most memorable symptom pattern in pheochromocytoma is the sudden spell. A person feels fine, then develops a pounding headache, marked palpitations, sweating, tremor, flushing or pallor, and a sense of severe internal activation. Blood pressure may spike during the episode, sometimes dramatically. The spell may last minutes to an hour or more, then ease. That classic pattern is what makes pheochromocytoma so often confused with panic attacks, hyperthyroidism, or severe anxiety.
The classic symptom triad is headache, palpitations, and sweating. Not every patient has all three, and not every person with those symptoms has the tumor. Still, that combination becomes more important when it is repetitive, severe, and accompanied by documented hypertension or an adrenal mass. Some people also describe chest tightness, nausea, tremor, anxiety, dizziness, shortness of breath, or a feeling of impending doom during attacks.
Blood pressure patterns can vary. Some patients have sustained hypertension. Others have paroxysmal surges with more normal readings in between. One of the most useful modern points is that pheochromocytoma is not limited to people with constant high blood pressure. A meaningful minority of patients may not be frankly hypertensive at rest, especially depending on how the tumor secretes hormones and how it was discovered. That is one reason an “I am not always hypertensive” history does not entirely rule it out.
Trigger patterns can also offer clues. Episodes may occur spontaneously, but they can be provoked by surgery, anesthesia, certain drugs, intense exertion, stress, urination in the case of bladder paraganglioma, or pressure on the tumor. The symptoms are often startlingly physical, which is why patients sometimes feel misunderstood when they are told it is “just stress” before a proper evaluation is considered.
That said, symptom severity alone should not be used as proof. Many common conditions can look similar. For example, a closer look at thyroid-related panic-like symptoms shows how much overlap there can be between catecholamine excess and hyperthyroid states. Migraine, obstructive sleep apnea, stimulant use, medication withdrawal, cocaine or amphetamine exposure, and panic disorder can also create convincing look-alikes.
The most suspicious pattern is usually a cluster of features rather than one symptom in isolation. The signal gets stronger when:
- spells are repetitive and stereotyped
- blood pressure is high or surges during episodes
- symptoms are unusually intense or abrupt
- there is an adrenal incidentaloma
- there is a family history of related tumors or syndromes
- the patient is relatively young or has otherwise unexplained difficult hypertension
The key idea is that pheochromocytoma produces a symptom profile that is dramatic but not unique. Suspicion rises when the episodes are classic, recurrent, and paired with the right clinical context. That context is what separates “possible” from “worth testing now.”
When the Diagnosis Becomes More Likely
Because pheochromocytoma is rare, it is most useful to think about when the pre-test probability becomes high enough to justify a focused workup. In other words, when is it more than an interesting possibility? The answer usually lies in the clinical setting rather than in any single symptom.
One major setting is resistant, severe, or highly variable hypertension, especially when it comes with catecholamine-like spells. Pheochromocytoma is still an uncommon cause of high blood pressure overall, and even of resistant hypertension, but it deserves more consideration when the blood pressure picture is unusually volatile or episodic. This is also where it helps to remember that other endocrine causes of hypertension exist, such as primary aldosteronism as a missed blood pressure cause, so the workup should stay broader than one tumor alone.
Another setting is the adrenal incidentaloma. If an adrenal mass is found on imaging for an unrelated reason, ruling out pheochromocytoma becomes part of safe evaluation, even if the patient is not having textbook spells. That is because a silent tumor still matters greatly before biopsy, surgery, or other interventions that could provoke catecholamine release.
Hereditary risk strongly raises suspicion too. A personal or family history of MEN2, von Hippel-Lindau disease, SDHx-related tumors, or neurofibromatosis type 1 changes the threshold for testing. Younger age at diagnosis, bilateral tumors, multifocal disease, or extra-adrenal tumors also make a genetic contribution more likely.
Pregnancy is another important setting, because missed pheochromocytoma in pregnancy can be especially dangerous. Episodic hypertension, headaches, and palpitations may be mistaken for more common pregnancy-related problems unless the presentation is examined carefully. Similarly, unusual cardiomyopathy, recurrent unexplained hypertensive crises, or surgery complicated by extreme blood pressure swings should all make clinicians more alert to the possibility.
The diagnosis also becomes more plausible when the picture simply does not fit ordinary explanations. For example:
- recurrent “panic attacks” without a clear psychological pattern
- severe spells with pallor, tremor, and marked hypertension
- unexplained hyperadrenergic symptoms plus an adrenal mass
- catecholamine-type episodes that worsen with certain medications or procedures
- unexplained cardiomyopathy or stroke in the setting of adrenergic spells
At the same time, suspicion should stay proportional. A person with occasional palpitations during stress and normal evaluation does not need to assume they have a rare tumor. The right mindset is not “Could this theoretically be pheochromocytoma?” but rather “Does this combination of symptoms, blood pressure pattern, tumor findings, or family risk make targeted biochemical testing reasonable?”
That balance is one reason this diagnosis is best approached thoughtfully. Over-testing low-risk situations leads to false positives and anxiety. Under-testing the right clinical pattern can miss a dangerous but treatable condition. Suspicion becomes useful when it is anchored to context, not fear.
How Testing Usually Starts
The initial workup for suspected pheochromocytoma usually begins with biochemical testing, not with a scan ordered in isolation. The main first-line tests are plasma free metanephrines or 24-hour urinary fractionated metanephrines. These metabolites are preferred because tumors may release catecholamines in bursts, while metanephrines often provide a more stable signal that improves detection.
Which test is chosen depends on the clinical setting, local expertise, and how the sample can be collected most reliably. Plasma testing can be very sensitive, but it is also more vulnerable to false positives if the sample is drawn under poor conditions. Ideally, the patient is calm, rested, and lying supine for a period before the blood draw. Urinary testing can be useful as an alternative when plasma sampling conditions are difficult to optimize.
This is where preanalytic detail matters far more than most people realize. Testing during acute stress, severe illness, heavy physical exertion, or after certain medications can muddy the picture. That is why a lab result that is only mildly elevated often does not settle the diagnosis on its own. It may need repeat testing under better conditions or further clarification rather than a jump straight to definitive labeling.
When results are clearly elevated, imaging usually follows to locate the tumor. CT is commonly the first anatomical imaging study, especially for the abdomen and pelvis. MRI may be preferred in some settings, such as when radiation exposure should be minimized, when metastatic disease is suspected, or when certain anatomical questions need better soft-tissue detail. Functional imaging may be added in more complex cases, especially if metastatic or multifocal disease is a concern.
Some patients hear about the clonidine suppression test, but this is not a universal first step. It is more of a problem-solving test in selected cases, particularly when normetanephrine elevations are borderline and the main question is whether the abnormality reflects true catecholamine excess or sympathetic activation from another cause.
Testing should also include a careful medication and history review. Drugs that interfere with catecholamine pathways or assay interpretation can push results in the wrong direction. So can untreated sleep apnea, acute pain, or certain psychiatric states. That is why interpreting pheochromocytoma testing is often more nuanced than simply checking whether a number is above the lab range.
A helpful mindset is this:
- Start with the right biochemical test.
- Optimize the testing conditions as much as possible.
- Interpret the result in context, especially if only mildly abnormal.
- Move to imaging once the biochemical evidence is convincing.
- Keep an eye on mimics and confounders throughout the process.
This testing pathway matters because it protects against two common mistakes: missing a real tumor by under-testing the right patient, and over-calling pheochromocytoma after a poorly timed or weakly abnormal result. Good diagnosis is not only about ordering the correct test. It is about ordering it in the correct way and reading it in the right clinical frame.
What Can Cause False Alarms
False-positive results are one of the main reasons pheochromocytoma workups can become stressful and confusing. Because the disorder is rare, even a decent test can create more false alarms than true diagnoses when it is used in low-probability settings. That is why the quality of suspicion matters just as much as the choice of assay.
A common issue is medication interference. Norepinephrine reuptake-blocking drugs, some antidepressants, stimulants, decongestants, and other sympathomimetic agents can complicate the interpretation of metanephrines. Medication changes should never be made casually or without guidance, but a careful review of the drug list is essential before an abnormal test result is treated as definitive.
Physiologic stress is another major confounder. Acute illness, pain, panic, severe anxiety, recent exertion, and poor sampling conditions can all push catecholamine-related measures upward. This is especially important because many of the symptoms that prompted testing in the first place, such as panic-like episodes or surges of distress, are themselves states of sympathetic activation. The more hyperaroused the body is during sampling, the harder it can be to separate tumor secretion from stress biology.
Sleep apnea is a good example of a mimic that is easy to underestimate. Repeated sympathetic activation overnight can produce hypertension, palpitations, sweating, and biochemical noise. So can severe untreated anxiety or recurrent panic. That is why people exploring stress-related high-cortisol-type symptoms sometimes encounter pheochromocytoma in search results even when the real issue is a different stress pathway entirely.
Imaging can create confusion too. Not every adrenal lesion is a pheochromocytoma, and not every pheochromocytoma behaves in a perfectly textbook way. Occasionally, biochemical testing can be falsely reassuring, or an incidental mass can look worrisome before the endocrine context is clear. That is why diagnosis should integrate clinical presentation, biochemical data, and imaging rather than leaning too heavily on one piece alone.
A practical way to reduce false alarms is to ask three questions before reacting strongly to an abnormal result:
- Was the test ordered for a genuinely suspicious clinical pattern?
- Were the sampling conditions good enough for the chosen test?
- Are there medications or medical conditions that could have distorted the result?
This point cannot be overstated: a mildly abnormal metanephrine result is not the same thing as a confirmed pheochromocytoma. The more subtle the biochemical abnormality, the more important context becomes. By contrast, strong elevations in the right clinical setting carry much more weight and usually justify moving forward more directly.
The goal is not to make the testing pathway seem unreliable. It is actually very effective when used correctly. The goal is to explain why thoughtful interpretation matters so much. In a rare disease with serious consequences, both overcalling and undercalling the diagnosis can cause harm. A good workup protects against both.
What Happens After Diagnosis
Once pheochromocytoma is confirmed, the next steps usually focus on localization, safe preparation for treatment, genetics, and long-term follow-up. For localized disease, surgery is the main curative treatment. But with this tumor, the period before surgery matters almost as much as the operation itself.
That is because manipulating a catecholamine-secreting tumor without proper preparation can provoke extreme blood pressure instability. Patients with functional tumors typically need alpha-adrenergic blockade before surgery to reduce the risk of perioperative hypertensive crisis. In practice, clinicians also pay attention to salt and fluid intake before surgery so the circulation is better prepared and postoperative hypotension is less severe. Only after alpha blockade is established are other measures, such as heart rate control, considered if needed.
Surgical planning depends on tumor size, location, whether there is suspicion of metastatic disease, and whether the tumor is adrenal or extra-adrenal. Minimally invasive adrenalectomy is often used for many adrenal pheochromocytomas, while open surgery may be more appropriate in other situations, especially for some paragangliomas or more complex disease.
Genetic evaluation is now a major part of care rather than an optional add-on. Because hereditary pathogenic variants are common in these tumors, many experts recommend germline testing for all patients with confirmed pheochromocytoma or paraganglioma. The result can change follow-up intensity, influence whether other tumors are screened for, and guide testing in family members. It can also help identify patients at higher risk for multifocal or metastatic disease, especially in certain SDHx-related syndromes.
Some tumors are metastatic or high-risk rather than fully localized. In that setting, treatment becomes more individualized and may include surgery, radiopharmaceutical therapy, functional imaging-guided approaches, and systemic treatments. The main point for a general reader is that the diagnosis does not stop at “remove the adrenal mass.” The condition has a genetics story, a surveillance story, and sometimes a metastatic-risk story as well.
Follow-up is therefore important even after apparently successful surgery. Recurrent or new tumor events can occur years later, particularly in hereditary forms or higher-risk disease. That is one reason long-term care is ideally handled by a team that understands endocrine tumors, surgery, genetics, and follow-up planning.
For patients, one of the most surprising parts of diagnosis is often how much safer they feel once the condition is actually named. What looked like random, frightening body episodes becomes a coherent endocrine problem with a structured plan. That does not make it trivial, but it does make it manageable. The key is that treatment is not only about removing a tumor. It is about preparing safely, checking the genetic context, and planning follow-up that matches the real risk profile.
When to Suspect It and Get Checked
The decision to get checked for pheochromocytoma should usually come from pattern recognition rather than fear. Most people with headaches, sweating, or palpitations do not need a tumor workup. But some combinations of symptoms and context make the possibility real enough that evaluation becomes sensible.
It is worth raising the question with a clinician when you have:
- recurrent spells of headache, palpitations, and sweating
- documented blood pressure surges, especially with spells
- difficult-to-control or highly variable hypertension
- an adrenal incidentaloma
- a family history of pheochromocytoma, paraganglioma, MEN2, VHL, NF1, or SDHx-related tumors
- unusual catecholamine-like episodes during pregnancy
- unexplained cardiomyopathy or crises during surgery or anesthesia
- young age with striking adrenergic symptoms or unusual hypertension
Urgent care is more appropriate if symptoms become extreme, especially with severe hypertension, chest pain, neurologic symptoms, or signs of crisis. A catecholamine crisis can be dangerous, and rapidly escalating symptoms should not be managed as a research project at home.
It is also worth emphasizing who should not automatically assume they have pheochromocytoma. If symptoms are mild, non-specific, and unaccompanied by hypertension, adrenal findings, or hereditary risk, the diagnosis is usually far less likely than more common explanations. Conditions such as panic disorder, hyperthyroidism, sleep apnea, migraine, stimulant use, and other endocrine disorders may be much higher on the list. A page on when endocrine symptoms merit specialist evaluation can help frame that threshold in a more balanced way.
At the same time, rarity should not become dismissal. A person with classic spells and repeated hypertensive episodes may be told for months that it is anxiety, especially if they look well between attacks. That is where persistence and good documentation help. Bring blood pressure readings if you have them. Note the duration and frequency of spells. Record triggers, medications, family history, and whether an adrenal lesion has already been seen on imaging. Specific information makes a focused workup much easier.
The best final takeaway is that pheochromocytoma is neither the hidden answer to every adrenaline-like symptom nor a diagnosis so rare that it can be ignored. It sits in the middle: uncommon, but important when the clues line up. The right question is not “Could I possibly have this?” but “Do my symptoms, blood pressure pattern, imaging, or family risk make it reasonable to check?”
That is a much calmer and more useful way to suspect it. It keeps the diagnosis in the right place: serious enough to recognize, rare enough to approach carefully, and treatable enough that timely testing can make a real difference.
References
- Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025 – PMC 2025 (Guideline)
- Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment – PMC 2024 (Review)
- Update on clinical characteristics in the evaluation of phaeochromocytoma and paraganglioma – PubMed 2024 (Review)
- Management of Pheochromocytomas and Paragangliomas – PubMed 2024 (Review)
- Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline – PubMed 2014 (Guideline)
Disclaimer
This article is for educational purposes only and is not a substitute for personal medical advice, diagnosis, or treatment. Pheochromocytoma is rare, but symptoms such as severe blood pressure spikes, pounding headaches, palpitations, sweating, chest pain, neurologic symptoms, or repeated hyperadrenergic spells should be medically assessed in the right clinical context. Do not stop blood pressure medicines, psychiatric medicines, or other prescribed treatments on your own in response to a suspected endocrine diagnosis.
If this article helped, please consider sharing it on Facebook, X, or another platform where it may help someone understand when pheochromocytoma is a realistic concern and when targeted testing makes sense.
